Moderna Inc. (NASDAQ:MRNA) shares are trading higher Monday after the company said it expects FY21 product sales of approximately $17.5 billion. Throughout 2021 the company shipped approximately 807 million doses of the Moderna COVID-19 vaccine. About 25% of all doses went to low and middle income countries through direct sales by Moderna and donations from high income countries.

• The price looks to have climbed back higher and is sitting slightly above the higher low trendline again. If the higher low trendline ends up holding as an area of resistance, the stock could see another bearish push.
• If Moderna bulls gain momentum and the stock continues to climb, resistance is shown to be near the $460 level.
• The stock trades below both the 50-day moving average (green) and the 200-day moving average (blue). This indicates bearish sentiment, and each of these moving averages may hold as an area of resistance in the future.
• The Relative Strength Index (RSI) saw a slight move higher and sits at 41 on the indicator. This slight move higher shows that more buyers have entered the market, although sellers still are in control of the stock. If the RSI can keep rising, buyers may take control over the stock soon.